VRTX

VERTEX PHARMACEUTICALS INC

VRTX·92532F100·US·Common Stock·Healthcare - Biotechnology-13D/G

VRTX (VERTEX PHARMACEUTICALS INC) is held by 347 institutional investors as of Q1 2026. Largest holders: Capital World Investors ($11.3B), BlackRock, Inc. ($10.7B), Capital Research Global Investors ($9.4B). Net institutional sentiment: Mixed. In Q1 2026, 2 members of Congress and 183 funds bought VRTX.

347
Holders
(31 Elite)
$98.1B
Total Value
52% (354)
Consensus
183 buying - 171 selling
13F: Insider & Congress:
VRTXSmart Money Verdict
View all
Held by 347 funds
31 elite
Who's Trading
InsiderBCBozic CarmenSell $614KMay 15, 2026
ActivistCapital World InvestorsCapital World Investors10.1%May 14, 2026
InsiderBCBozic CarmenSell $3.1MMay 12, 2026
InsiderBNBhatia Sangeeta N.Sell $135KMay 4, 2026
InsiderLJLiu JoySell $469KMay 1, 2026
ActivistVAVanguard Capital Management7.5%Apr 30, 2026
CongressRohit KhannaRohit KhannaBuy $1,001 - $15,000Apr 24, 2026
CongressRohit KhannaRohit KhannaBuyApr 13, 2026
CongressRohit KhannaRohit KhannaBuy $1,001 - $15,000Mar 30, 2026
CongressRohit KhannaRohit KhannaBuy $1,001 - $15,000Mar 23, 2026
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Decreased
25.4M(-0.6%)$11.3B1.5%+59.23%
0
Increased
24M(+0.9%)$10.7B0.2%+20.29%
38
Increased
21.1M(+22.0%)$9.4B1.5%+10.56%
60
New
16.5M$7.4B0.2%+2.34%
53
Increased
11.7M(+0.3%)$5.2B0.2%+19.03%
38
Increased
7M(+16.4%)$3.1B0.2%+14.69%
44
Increased
6.1M(+2.6%)$2.7B0.2%+94.64%
39
New
5.1M$2.3B0.1%+2.34%
53
Increased
5.1M(+8.3%)$2.3B0.5%+14.00%
49
Decreased
4M(-0.7%)$1.8B2.4%+98.60%
0
Decreased
3.9M(-13.0%)$1.8B0.6%+104.41%
0
Decreased
3.2M(-15.9%)$1.4B0.3%+46.18%
0
Increased
3.2M(+2.2%)$1.4B0.1%+3.77%
33
Increased
3.1M(+1.9%)$1.4B0.3%+71.72%
39
Decreased
2.9M(-2.0%)$1.3B0.1%+16.97%
0
Decreased
2.7M(-15.7%)$1.2B0.8%+30.73%
0
Decreased
2.7M(-5.6%)$1.2B1.0%+68.52%
0
Increased
2.6M(+16.3%)$1.2B0.3%+70.06%
44
Decreased
2.6M(-0.6%)$1.1B0.2%+111.80%
0
Increased
2.6M(+19.0%)$1.1B0.2%+44.50%
45

Showing 1-20 of 359

1 / 18

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used